Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells

Leukemia

Volumn 21, Issue 10, 2007, Pages 2103-2108

  Kato, N ^a   Tanaka, J ^a   Sugita, J ^a   Toubai, T ^a   Miura, Y ^a   Ibata, M ^a   Syono, Y ^a   Ota, S ^a   Kondo, T ^a   Asaka, M ^a   Imamura, M ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD8 ANTIGEN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; TRICHOSTATIN A;

ACETYLATION; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEUKEMIA CELL; LYMPHOBLASTOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR CELL; TUMOR IMMUNITY; UPREGULATION;

EID: 34548779134     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404862     Document Type: Article

References (38)

1. Cerwenka A, Lanier LL. NKG2D ligands: Unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003; 61: 335-343.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
3. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-260.
4. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076-1086.
5. Bahram S. MIC genes: From genetics to biology. Adv Immunol 2000; 76: 1-60.
6. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
7. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178-6186.
8. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
9. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-6884.
10. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 2006; 118: 1445-1452.
11. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-6329.
12. Conejo-Garcia JR, Benencia F, Courreges MC, Gimotty PA, Khang E, Buckanovich RJ et al. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28-antitumor T cells. Cancer Res 2004; 64: 2175-2182.
13. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-1396.
14. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004; 18 2002-2007.
15. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251-258.
16. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64: 9172-9179.
17. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-790.
18. Zhang C, Zhang J, Wei H, Tian Z. Imbalance of NKG2D and its inhibitory counterparts: How does tumor escape from innate immunity? Int Immunopharmacol 2005; 5: 1099-1111.
19. Bubenik J. MHC class I down-regulation: Tumour escape from immune surveillance? (review). Int J Oncol 2004; 25: 487-491.
20. Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 2002; 59: 241-257.
21. Fang JY, Lu YY. Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J Gastroenterol 2002; 8: 400-405.
22. Kamitani H, Taniura S, Watanabe K, Sakamoto M, Watanabe T, Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro-oncol 2002; 4: 95-101.
23. Woodcock DM, Linsenmeyer ME, Doherty JP, Warren WD. DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer 1999; 79: 251-256.
24. Rouhi A, Gagnier L, Takei F, Mager DL. Evidence for epigenetic maintenance of Ly49A monoallelic gene expression. J Immunol 2006; 176: 2991-2999.
25. Chan HW, Miller JS, Moore MB, Lutz CT. Epigenetic control of highly homologous killer Ig-like receptor gene alleles. J Immunol 2005; 175: 5966-5974.
26. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016-7025.
27. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-967.
28. Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 2006; 115: 78-90.
29. Tanaka J, Toubai T, Tsutsumi Y, Miura Y, Kato N, Umehara S et al. Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 2004; 104: 768-774.
30. Tanaka J, Iwao N, Toubai T, Tsutsumi Y, Miura Y, Kato N et al. Cytolytic activity against primary leukemic cells by inhibitory NK cell receptor (CD94/NKG2A)-expressing T cells expanded from various sources of blood mononuclear cells. Leukemia 2005; 19: 486-489.
31. Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M et al. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol 2002; 22: 8302-8319.
32. Ashburner BP, Westerheide SD, Baldwin Jr AS. The p65 (ReIA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001; 21: 7065-7077.
33. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13.
34. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693-6701.
35. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013-1020.
36. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-568.
37. Salih HR, Rammensee HG, Steinle A. Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169 4098-4102.
38. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006; 118: 684-687.